Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation

20 May 2020

Abstract excerpt

disruption was observed in vivo (~48%), significantly reducing the expression of PCSK9 and gaining the therapeutic benefit of cholesterol control (~45% of cholesterol reduction).

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Innovation and Socioeconomic Development
Share to Mosquito-borne diseases and control

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32490205
DOI: 10.1126/sciadv.aba2983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulationPMID 32490205Read ↗

CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis.Semantic proximity Read ↗

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primatesSemantic proximity Read ↗

Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable <i>Pcsk9</i> Silencing in a Clinically Relevant Delivery SystemSemantic proximity Read ↗

Gene Editing for the Treatment of HypercholesterolemiaSemantic proximity Read ↗

Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic ApplicationsSemantic proximity Read ↗

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and OpportunitiesSemantic proximity Read ↗

Treatment of Dyslipidemia Using CRISPR/Cas9 Genome EditingSemantic proximity Read ↗

CRISPR and cardiovascular diseasesSemantic proximity Read ↗

A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivoSemantic proximity Read ↗

Gene editing in common cardiovascular diseasesSemantic proximity Read ↗

Discovery and engineering of AiEvo2, a novel Cas12a nuclease for human gene editing applicationsSemantic proximity Read ↗

Viral delivery of compact CRISPR-Cas12f for <i>in vivo</i> gene editing applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.